Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

David Fogelman, Elizabeth Sugar, George Oliver, Neeraj Shah, Alison Klein, Christine Alewine, Huamin Wang, Milind Javle, Rachna Shroff, Robert A. Wolff, James L. Abbruzzese, Daniel Laheru, Luis A. Diaz

Research output: Contribution to journalArticle

Abstract

Purpose: Metastatic pancreatic adenocarcinoma is considered a uniformly fatal disease with a median survival of 1 year with modern chemotherapy. While a subset of patients achieve prolonged survival, few of the factors that define this group of patients are known. Methods: For the determination of overall survival (OS), 549 patients with histologically confirmed metastatic pancreatic adenocarcinoma were evaluated. Emphasis was placed on treatment history and family history of breast, ovarian, and pancreatic cancers. To ensure a uniform metastatic population, patients treated with prior locoregional therapies (i.e., surgery or radiotherapy) were excluded as were patients with a prior history of stage I-III disease. Results: Patients with family history or pedigree history of cancer had superior OS. This was especially true in patients with three or more relatives with either breast, ovarian, or pancreatic cancers [hazard ratio (HR) 0.49, 95 % confidence interval (CI) 0.30-0.80, p = 0.003]. First-line platinum chemotherapy was associated with a poor survival (hazard ratio for death 1.74, 95 % CI 1.12-2.71, p = 0.01) for patients without a family history of these cancers but not for those without such a history (p = 0.31). In fact, as the number of relatives with these cancers increased, the OS survival improved for individuals receiving first-line platinum therapy (HR 0.76, 95 % CI 0.65-0.89, p = 0.0004), which was not the case for those receiving other therapies (p = 0.98). Conclusions: Treatment with platinum chemotherapy in patients with a family history of breast, ovarian, or pancreatic cancers was associated with a longer survival, whereas platinum use in patients without such a family history of cancer was associated with poor survival. These findings suggest that family history may serve as a predictive marker for platinum use in patients with metastatic pancreatic adenocarcinoma.

Original languageEnglish (US)
Pages (from-to)489-498
Number of pages10
JournalCancer Chemotherapy and Pharmacology
Volume76
Issue number3
DOIs
StatePublished - Jul 1 2015

Fingerprint

Platinum
Adenocarcinoma
Chemotherapy
Hazards
Survival
Pancreatic Neoplasms
Ovarian Neoplasms
Radiotherapy
Confidence Intervals
Breast Neoplasms
Surgery
Drug Therapy
Neoplasms
History
Therapeutics
Pedigree

Keywords

  • BRCA
  • Chemotherapy
  • Family history
  • Pancreatic adenocarcinoma
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Pharmacology
  • Pharmacology (medical)
  • Toxicology

Cite this

Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. / Fogelman, David; Sugar, Elizabeth; Oliver, George; Shah, Neeraj; Klein, Alison; Alewine, Christine; Wang, Huamin; Javle, Milind; Shroff, Rachna; Wolff, Robert A.; Abbruzzese, James L.; Laheru, Daniel; Diaz, Luis A.

In: Cancer Chemotherapy and Pharmacology, Vol. 76, No. 3, 01.07.2015, p. 489-498.

Research output: Contribution to journalArticle

Fogelman, D, Sugar, E, Oliver, G, Shah, N, Klein, A, Alewine, C, Wang, H, Javle, M, Shroff, R, Wolff, RA, Abbruzzese, JL, Laheru, D & Diaz, LA 2015, 'Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma', Cancer Chemotherapy and Pharmacology, vol. 76, no. 3, pp. 489-498. https://doi.org/10.1007/s00280-015-2788-6
Fogelman, David ; Sugar, Elizabeth ; Oliver, George ; Shah, Neeraj ; Klein, Alison ; Alewine, Christine ; Wang, Huamin ; Javle, Milind ; Shroff, Rachna ; Wolff, Robert A. ; Abbruzzese, James L. ; Laheru, Daniel ; Diaz, Luis A. / Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma. In: Cancer Chemotherapy and Pharmacology. 2015 ; Vol. 76, No. 3. pp. 489-498.
@article{81e590028aae433b81cd5ce419aec7ef,
title = "Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma",
abstract = "Purpose: Metastatic pancreatic adenocarcinoma is considered a uniformly fatal disease with a median survival of 1 year with modern chemotherapy. While a subset of patients achieve prolonged survival, few of the factors that define this group of patients are known. Methods: For the determination of overall survival (OS), 549 patients with histologically confirmed metastatic pancreatic adenocarcinoma were evaluated. Emphasis was placed on treatment history and family history of breast, ovarian, and pancreatic cancers. To ensure a uniform metastatic population, patients treated with prior locoregional therapies (i.e., surgery or radiotherapy) were excluded as were patients with a prior history of stage I-III disease. Results: Patients with family history or pedigree history of cancer had superior OS. This was especially true in patients with three or more relatives with either breast, ovarian, or pancreatic cancers [hazard ratio (HR) 0.49, 95 {\%} confidence interval (CI) 0.30-0.80, p = 0.003]. First-line platinum chemotherapy was associated with a poor survival (hazard ratio for death 1.74, 95 {\%} CI 1.12-2.71, p = 0.01) for patients without a family history of these cancers but not for those without such a history (p = 0.31). In fact, as the number of relatives with these cancers increased, the OS survival improved for individuals receiving first-line platinum therapy (HR 0.76, 95 {\%} CI 0.65-0.89, p = 0.0004), which was not the case for those receiving other therapies (p = 0.98). Conclusions: Treatment with platinum chemotherapy in patients with a family history of breast, ovarian, or pancreatic cancers was associated with a longer survival, whereas platinum use in patients without such a family history of cancer was associated with poor survival. These findings suggest that family history may serve as a predictive marker for platinum use in patients with metastatic pancreatic adenocarcinoma.",
keywords = "BRCA, Chemotherapy, Family history, Pancreatic adenocarcinoma, Survival",
author = "David Fogelman and Elizabeth Sugar and George Oliver and Neeraj Shah and Alison Klein and Christine Alewine and Huamin Wang and Milind Javle and Rachna Shroff and Wolff, {Robert A.} and Abbruzzese, {James L.} and Daniel Laheru and Diaz, {Luis A.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1007/s00280-015-2788-6",
language = "English (US)",
volume = "76",
pages = "489--498",
journal = "Cancer Chemotherapy and Pharmacology",
issn = "0344-5704",
publisher = "Springer Verlag",
number = "3",

}

TY - JOUR

T1 - Family history as a marker of platinum sensitivity in pancreatic adenocarcinoma

AU - Fogelman, David

AU - Sugar, Elizabeth

AU - Oliver, George

AU - Shah, Neeraj

AU - Klein, Alison

AU - Alewine, Christine

AU - Wang, Huamin

AU - Javle, Milind

AU - Shroff, Rachna

AU - Wolff, Robert A.

AU - Abbruzzese, James L.

AU - Laheru, Daniel

AU - Diaz, Luis A.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Purpose: Metastatic pancreatic adenocarcinoma is considered a uniformly fatal disease with a median survival of 1 year with modern chemotherapy. While a subset of patients achieve prolonged survival, few of the factors that define this group of patients are known. Methods: For the determination of overall survival (OS), 549 patients with histologically confirmed metastatic pancreatic adenocarcinoma were evaluated. Emphasis was placed on treatment history and family history of breast, ovarian, and pancreatic cancers. To ensure a uniform metastatic population, patients treated with prior locoregional therapies (i.e., surgery or radiotherapy) were excluded as were patients with a prior history of stage I-III disease. Results: Patients with family history or pedigree history of cancer had superior OS. This was especially true in patients with three or more relatives with either breast, ovarian, or pancreatic cancers [hazard ratio (HR) 0.49, 95 % confidence interval (CI) 0.30-0.80, p = 0.003]. First-line platinum chemotherapy was associated with a poor survival (hazard ratio for death 1.74, 95 % CI 1.12-2.71, p = 0.01) for patients without a family history of these cancers but not for those without such a history (p = 0.31). In fact, as the number of relatives with these cancers increased, the OS survival improved for individuals receiving first-line platinum therapy (HR 0.76, 95 % CI 0.65-0.89, p = 0.0004), which was not the case for those receiving other therapies (p = 0.98). Conclusions: Treatment with platinum chemotherapy in patients with a family history of breast, ovarian, or pancreatic cancers was associated with a longer survival, whereas platinum use in patients without such a family history of cancer was associated with poor survival. These findings suggest that family history may serve as a predictive marker for platinum use in patients with metastatic pancreatic adenocarcinoma.

AB - Purpose: Metastatic pancreatic adenocarcinoma is considered a uniformly fatal disease with a median survival of 1 year with modern chemotherapy. While a subset of patients achieve prolonged survival, few of the factors that define this group of patients are known. Methods: For the determination of overall survival (OS), 549 patients with histologically confirmed metastatic pancreatic adenocarcinoma were evaluated. Emphasis was placed on treatment history and family history of breast, ovarian, and pancreatic cancers. To ensure a uniform metastatic population, patients treated with prior locoregional therapies (i.e., surgery or radiotherapy) were excluded as were patients with a prior history of stage I-III disease. Results: Patients with family history or pedigree history of cancer had superior OS. This was especially true in patients with three or more relatives with either breast, ovarian, or pancreatic cancers [hazard ratio (HR) 0.49, 95 % confidence interval (CI) 0.30-0.80, p = 0.003]. First-line platinum chemotherapy was associated with a poor survival (hazard ratio for death 1.74, 95 % CI 1.12-2.71, p = 0.01) for patients without a family history of these cancers but not for those without such a history (p = 0.31). In fact, as the number of relatives with these cancers increased, the OS survival improved for individuals receiving first-line platinum therapy (HR 0.76, 95 % CI 0.65-0.89, p = 0.0004), which was not the case for those receiving other therapies (p = 0.98). Conclusions: Treatment with platinum chemotherapy in patients with a family history of breast, ovarian, or pancreatic cancers was associated with a longer survival, whereas platinum use in patients without such a family history of cancer was associated with poor survival. These findings suggest that family history may serve as a predictive marker for platinum use in patients with metastatic pancreatic adenocarcinoma.

KW - BRCA

KW - Chemotherapy

KW - Family history

KW - Pancreatic adenocarcinoma

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=84939566713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939566713&partnerID=8YFLogxK

U2 - 10.1007/s00280-015-2788-6

DO - 10.1007/s00280-015-2788-6

M3 - Article

C2 - 26126726

AN - SCOPUS:84939566713

VL - 76

SP - 489

EP - 498

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

SN - 0344-5704

IS - 3

ER -